Nektar Therapeutics（NKTR）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · NKTR · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$55.23M	$98.43M	$90.12M	$92.06M	$101.91M
Cost of Revenue	$0.00M	$30.69M	$36.64M	$21.64M	$24.90M
Gross Profit	$55.23M	$67.74M	$53.48M	$70.42M	$77.01M
Gross Margin %(computed)	100.00%	68.82%	59.34%	76.50%	75.57%
Operating Expenses
R&D Expenses	$117.33M	$120.91M	$114.16M	$218.32M	$400.27M
G&A Expenses	$68.67M	$76.75M	$77.42M	$92.33M	$122.84M
Total Operating Expenses	$186.00M	$172.94M	$190.90M	$310.66M	$523.11M
Operating Income	($130.77M)	($105.20M)	($137.43M)	($240.24M)	($446.10M)
Operating Margin %(computed)	-236.77%	-106.88%	-152.49%	-260.97%	-437.76%
Interest Income	$10.44M	$14.50M	$19.01M	$6.78M	$2.73M
Interest Expense	$26.18M	$28.11M	$25.33M	$28.91M	$47.31M
Income Before Tax	($164.21M)	($119.20M)	($276.26M)	($364.98M)	($523.28M)
Income Tax Expense	($0.14M)	($0.24M)	($0.20M)	$3.21M	$0.56M
Net Income	($164.08M)	($118.96M)	($276.06M)	($368.20M)	($523.84M)
Net Margin %(computed)	-297.07%	-120.86%	-306.31%	-399.98%	-514.03%
Per Share & EBITDA
EPS (Basic)	$-9.73	$-8.68	$-21.79	$-29.51	$-42.90
Wtd Avg Shares	16.87M	13.71M	12.67M	12.48M	12.22M
EBITDA	($129.74M)	($86.70M)	($243.11M)	($323.87M)	($461.82M)
EBITDA Margin %(computed)	-234.91%	-88.08%	-269.75%	-351.82%	-453.18%